Qu Biologics’ Crohn’s Disease Clinical Trial Completes Independent Safety Review
An independent DSMC has reviewed the safety data generated from 30 patients (50% enrollment) from Qu Biologics' current Crohn's disease clinical trial and has recommended that the trial continue as...
View ArticleJ&J Buys Rights to Vedanta’s Bowel Disease Drug
J&J’s Janssen Pharmaceutical Companies unit says Vedanta Biosciences could receive up to US$241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel...
View ArticleLonza to Make Crohn’s Disease Stem-cell Therapy for TiGenix
Lonza will manufacture the Cx601 product for TiGenix's Phase 3 trial in the US at Lonza's Walkersville, Maryland (US) facility The post Lonza to Make Crohn’s Disease Stem-cell Therapy for TiGenix...
View ArticlePerrigo Buys Entocort from AstraZeneca
Perrigo said Entocort, a gastroenterology medicine for patients with mild to moderate Crohn's disease, has exhibited “consistent” revenue streams since the launch of limited generic competition in...
View ArticleGlobal Autoimmune Diseases Treatment Market to Grow US$52M by 2022
The autoimmune diseases treatment market was valued at US$40,944.9 million in 2015, and is expected to reach US$52,456.3 million by 2022, expanding at a CAGR of 3.53% from 2016 to 2022. This is...
View ArticleRedHill Biopharma announces positive and unanimous DSMB recommendation for...
Following a pre-planned review of safety data, RedHill has received a unanimous recommendation from the DSMB to continue the MAP US Phase III study with RHB-104 for Crohn’s disease as planned, without...
View ArticleNew analyses support the effectiveness and safety of Entyvio (vedolizumab)
Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium. The post New analyses support the effectiveness and safety of Entyvio...
View ArticleRedHill Biopharma announces continuation of Phase III Study with RHB-104 for...
The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the...
View Article
